Curcumin-based nanotherapeutics - Laila Pharmaceuticals

Drug Profile

Curcumin-based nanotherapeutics - Laila Pharmaceuticals

Alternative Names: LP-001-09; LP-002-09; LP-004-09; LP-005-09; LP-013-09; LPCVD; LPD-1050; LPG-1030-I; LPG-1030-S; LPMD; LPO-1010-AM; LPO-1010-CA; LPO-1010-CSR; LPO-1010-DR; LPO-1010-UV

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laila Pharmaceuticals
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Cyclo-oxygenase 2 inhibitors; HIV integrase inhibitors; Immunosuppressants; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration; Cataracts
  • Preclinical Cardiovascular disorders; Central serous chorioretinopathy; Diabetes mellitus; Diabetic retinopathy; Inflammatory bowel diseases; Irritable bowel syndrome; Uveitis
  • No development reported Allergic conjunctivitis; Alzheimer's disease; HIV infections; Osteoarthritis; Psoriasis; Stomatitis

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Psoriasis in India (Topical, Cream)
  • 16 Mar 2016 Clinical development for Cataracts is ongoing in India
  • 16 Mar 2016 No recent reports on development identified - Phase-II for Allergic conjunctivitis in India (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top